These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7376137)

  • 21. Tryptophan 60-D in the B-insertion loop of thrombin modulates the thrombin-antithrombin reaction.
    Rezaie AR
    Biochemistry; 1996 Feb; 35(6):1918-24. PubMed ID: 8639675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the molecular mass dependency of heparin stimulation of heparin cofactor II:thrombin interaction to antithrombin III:thrombin interaction.
    Scully MF; Ellis V; Kakkar VV
    Thromb Res; 1987 May; 46(3):491-502. PubMed ID: 3603437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ostrich antithrombin III: kinetics and mechanism of inhibition of ostrich thrombin.
    Frost CL; Naudé RJ; Muramoto K
    Int J Biochem Cell Biol; 2002 Sep; 34(9):1164-71. PubMed ID: 12009311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Purification and characterization of hereditary abnormal antithrombin III with impaired thrombin binding.
    Jørgensen M; Petersen LC; Thorsen S
    J Lab Clin Med; 1984 Aug; 104(2):245-56. PubMed ID: 6747440
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conformational changes accompanying the binding of antithrombin III to thrombin.
    Villanueva G; Danishefsky I
    Biochemistry; 1979 Mar; 18(5):810-7. PubMed ID: 420817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of sulfated xylans during the interaction of [125I]-thrombin with antithrombin III or heparin cofactor II of human plasma.
    Simmons RB; Newton GR; Doctor VM
    Eur J Drug Metab Pharmacokinet; 1995; 20(1):73-7. PubMed ID: 7588997
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Demonstration of altered antithrombin III activity due to nonenzymatic glycosylation at glucose concentration expected to be encountered in severely diabetic patients.
    Villanueva GB; Allen N
    Diabetes; 1988 Aug; 37(8):1103-7. PubMed ID: 3391345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Permeability of a heparin-polyvinyl alcohol hydrogel to thrombin and antithrombin III.
    Smith BA; Sefton MV
    J Biomed Mater Res; 1988 Aug; 22(8):673-85. PubMed ID: 3215905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ability of high-affinity heparin fractions with decreasing affinity for antithrombin III to activate ATIII isoforms.
    Carlson TH; Kolman MR; Frees A; Babcock T
    Thromb Res; 1990 Aug; 59(3):521-30. PubMed ID: 2237824
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heparin-like tubings. II. Mechanism of the thrombin-antithrombin III reaction at the surface.
    Migonney V; Fougnot C; Jozefowicz M
    Biomaterials; 1988 May; 9(3):230-4. PubMed ID: 3408793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heparin and protease inhibition. I. Heparin complexes with thrombin, plasmin, and trypsin.
    Smith GF; Sundboom JL
    Thromb Res; 1981 Apr 1-15; 22(1-2):103-14. PubMed ID: 6457413
    [No Abstract]   [Full Text] [Related]  

  • 32. The interaction of proteases, antithrombin III, and heparin.
    Downing MR
    J Lab Clin Med; 1980 Jun; 95(6):777-82. PubMed ID: 6991619
    [No Abstract]   [Full Text] [Related]  

  • 33. Inhibition of heparin-catalyzed human antithrombin III activity by nonenzymatic glycosylation. Possible role in fibrin deposition in diabetes.
    Brownlee M; Vlassara H; Cerami A
    Diabetes; 1984 Jun; 33(6):532-5. PubMed ID: 6724150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.
    Weitz JI; Hudoba M; Massel D; Maraganore J; Hirsh J
    J Clin Invest; 1990 Aug; 86(2):385-91. PubMed ID: 2384594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of protamine sulfate on antithrombin III activity.
    Matsuo T; Shanberge JN; Matsuo O
    Clin Chim Acta; 1983 Jul; 131(3):233-8. PubMed ID: 6883717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Study of anticoagulant mechanism of low molecular weight heparin.
    Hamano S; Nishiyama M; Komatsu H; Miyata H; Ikeda S; Sakuragawa N
    Thromb Res; 1992 Mar; 65(6):801-8. PubMed ID: 1321995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective disruption of heparin and antithrombin-mediated regulation of human factor IX.
    Westmark PR; Tanratana P; Sheehan JP
    J Thromb Haemost; 2015 Jun; 13(6):1053-63. PubMed ID: 25851619
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The interaction of immobilized thrombin with human antithrombin III.
    Marciniak E; Gora-Maslak G
    Thromb Haemost; 1984 Feb; 51(1):27-31. PubMed ID: 6719385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inactivation of thrombin by antithrombin III on a heparinized biomaterial.
    Goosen MF; Sefton MV; Hatton MW
    Thromb Res; 1980 Dec 1-15; 20(5-6):543-54. PubMed ID: 7233384
    [No Abstract]   [Full Text] [Related]  

  • 40. Inhibition of the heparin-antithrombin III/thrombin reaction by active site blocked-thrombin.
    Griffith MJ; Kingdon HS; Lundblad RL
    Biochem Biophys Res Commun; 1979 Apr; 87(3):686-92. PubMed ID: 454418
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.